Fate Investor Meeting Takeaways; Phase II RECLAIM-LN Study Start Soon

Research evidence excerpt

Fate Investor Meeting Takeaways; Phase II RECLAIM-LN Study Start Soon

outpatient setting. At 6 months, SLEDAI-2K scores dropped by an 10Q as of May 7th + PFWs + Series A

average of ~7 points from a baseline of ~11 points. FT819 also improved PGA scores and Convert

FACIT- fatigue scores. Bendamustine preconditioning achieved greater peak FT-819 Market Cap. (mil) US$256.4

expansion, deeper B cell depletion, better efficacy and re-populated naive B cells at 6 Total Assets ($mil) 285

Avg Daily Vol (000) 2,767 months. FT819 + bendamustine reduced UPCr to below the 0.5mg/mg level required

Book Value/Share US$1.34

for a complete renal response (cRR) at 6 months, which was durable for 24 months! Price/Book 143%

Fate is preparing to initiate the single-arm registrational Phase II RECLAIM-LN study Net Cash Per Share US$1.30

(NCT07570862) in 53 LN patients to receive a single administration of 900M FT819 Debt to Total Capital 0.0%

cells with bendamustine preconditioning with 6-month cRR as the primary endpoint. Fate Div Yield 0.00%

aims to report interim data in mid'27 and file the BLA in 2028. Fate plans to align with Fiscal Year End Dec

the FDA on the primary endpoint for a registrational Phase II study in extrarenal lupus

(ERL) patients in 2H:26. Price Performance - 1 Year

USD

• Phase I FT839 Study Start in 2026. FT839 is a dual CD19/CD38 CAR-iT with 13 edits 3

for enhanced immune evasion and potency. Preclinical data in RA patient samples show 2.5

FT839 targeted a broad immune cell population, which could be applied beyond B cell

mediated autoimmune diseases. FT839 is engineered with hnCD16 and a CD3 fusion 2

receptor enabling combination with mAbs and T cell engagers. Importantly, FT839 is 1.5